# Commercial/Healthcare Exchange PA Criteria

***Effective: June 3, 2020***

***Prior Authorization:*** Nurtec ODT™

***Products Affected:*** Nurtec (rimegepant) orally disintegrating tablets

***Medication Description:*** Nurtec ODT (rimegepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.

***Covered Uses:***
1. The acute treatment of migraine with or without aura in adults.
2. Preventive treatment of episodic migraine in adults.

***Exclusion Criteria:***
1. Concurrent use (for example, during the same time period) of two CGRP inhibitors indicated for the preventative treatment of migraine (for example, Aimovig, Ajovy, Emgality, Qulipta, Vyepti)

***Required Medical Information:***
1. Diagnosis
2. Previous therapies tried and failed

***Age Restrictions:*** 18 years of age or older

***Prescriber Restrictions:*** None

***Coverage Duration:*** 12 months

***Other Criteria:***

**I. Initial Criteria**

**1. Acute Migraine with or without Aura**: Approve Nurtec ODT if the patient meets all of the following criteria:
   A. The patient has a diagnosis of acute migraine with or without aura; **AND**
   B. The patient meets **ONE** of the following (i **or** ii):
      i. Patient has tried at least **one** triptan therapy; **OR**
      ii. The patient has an intolerance or contraindication to triptan(s) according to the prescriber defined as (but not limited to):
         a. Allergic reaction
         b. Adverse drug reactions

**2. Preventative Treatment of Episodic Migraine:** Approve for 1 year if the patient meets all the following criteria:
   A. Patient is ≥ 18 years of age; **AND**

B. Patient has ≥ 4 and < 15 migraine headache days per month (prior to initiating a migraine-preventive medication); **AND**

C. Patient has tried at least **two** standard prophylactic (preventive) pharmacologic therapies, each from a different pharmacologic class; **AND**

*Note: Examples of standard prophylactic (preventive) pharmacologic therapies include angiotensin receptor blocker, angiotensin converting enzyme inhibitor, anticonvulsant, beta-blocker, calcium channel blocker, tricyclic antidepressant, other antidepressant.*

D. Patient meets **ONE** of the following criteria (i, ii, **or** iii):

i. Patient has had inadequate efficacy to both of those standard prophylactic (preventive) pharmacologic therapies, according to the prescriber; **OR**

ii**.** Patient has experienced adverse event(s) severe enough to warrant discontinuation of both of those standard prophylactic (preventive) pharmacologic therapies, according to the prescriber; **OR**

iii. Patient has had inadequate efficacy to one standard prophylactic (preventive) pharmacologic therapy and has experienced adverse event(s) severe enough to warrant discontinuation of another standard prophylactic (preventive) pharmacologic therapy, according to the prescriber; **AND**

E. Patient is currently taking Nurtec ODT and has had a significant clinical benefit from the medication as determined by the prescriber.

*Note: Examples of significant clinical benefit include a reduction in the overall number of migraine days per month or a reduction in number of severe migraine days per month from the time that Nurtec ODT was initiated.*

**II. Continuation Criteria**

1. Patient has experienced a positive clinical response to therapy (ie. reduction in headache pain severity, relief from other migraine symptoms [photophobia, phonophobia or nausea], sustained headache pain relief, and improved ability to function normally reduction in the overall number of migraine days per month or a reduction in number of severe migraine days per month from the time that Nurtec ODT was initiated.)

***References:***

1. Nurtec ODT [prescribing information]. New Haven, CT: Biohaven Pharmaceuticals; February 2020.

***Policy Revision history***

| Rev # | Type of Change | Summary of Change | Sections Affected | Date |
|---|---|---|---|---|
| 1 | New Policy | New Policy | All | 6/3/2020 |

| | | | | |
|---|---|---|---|---|
| 2 | Policy update | Added Continuation Criteria: Patient has experienced a positive clinical response to therapy (e.g., reduction in headache pain severity, relief from other migraine symptoms [photophobia, phonophobia or nausea], sustained headache pain relief, and improved ability to function normally). | Other criteria | 1/11/2021 |
| 3 | Policy update | Modified Initial Criteria to remove "patient has tried two triptan therapies," to "patient has tried at least one triptan therapy | Other Criteria | 12/8/2021 |
| 4 | Policy update | Removed from Initial Criteria: "*Patient meets ONE of the following (i or ii): i.Patient is NOT taking Nurtec ODT and meets ONE of the following (a or b): a. Patient has tried at least one triptan therapy; OR b. Patient has a contraindication to triptan(s) according to the prescriber; OR Note: Examples of contraindications to triptans include a history of coronary artery disease; cardiac accessory conduction pathway disorders; history of stroke, transient ischemic attack, or hemiplegic or basilar migraine; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; or severe hepatic impairment*" | Initial Criteria | 8/18/2022 |